Psyence Biomedical Ltd.

PBM

CA74449F4078

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-12 pm EDT			5-day change	1st Jan Change
3.330 ^USD	-4.58%		-5.13%	-29.28%

Apr. 24	FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain	MT
Apr. 23	Psyence Biomedical Ltd. Initiates Patient Dosing In Phase IIb Trial Evaluating NPX-5 For Adjustment Disorder	CI

Psyence Biomedical's chairman, Jody Aufrichtig, assumes role of CEO

Published on 10/09/2025 at 05:50 pm EDT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Psyence Biomedical Ltd.

Apr. 24	FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain	MT
Apr. 23	Psyence Biomedical Ltd. Initiates Patient Dosing In Phase IIb Trial Evaluating NPX-5 For Adjustment Disorder	CI
Apr. 22	Top Premarket Decliners	MT
Apr. 21	What to know about psychedelic therapies cited by Trump	RE
Apr. 20	Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness	MT
Apr. 17	Top Midday Gainers	MT
Apr. 17	Psyence Biomedical Ltd Advances Nature-Derived Psilocybin And Ibogaine Therapies	CI
Apr. 17	Top Premarket Gainers	MT
Apr. 08	Psyence Biomedical Ltd Expands Australian Clinical Site Network And Advances NPX-5 Supported Clinical Activities	CI
Mar. 03	Psyence Biomedical Ltd. Announces Export Of GMP-Manufactured Natural Psilocybin NPX-5 To Australia For Ongoing Phase IIb Clinical Trial	CI
Mar. 03	Psyence Biomed announces export of GMP-manufactured natural psilocybin (NPX-5) to Australia for ongoing clinical trial phase IIb	RE
Mar. 02	Psyence Biomedical Ltd. Announces Resignation and Appointment of Director and Changes in Board Committee Composition, Effective February 20, 2026	CI
Feb. 11	Psyence Biomed announces settlement of shareholder litigation	RE
Feb. 03	Top Premarket Decliners	MT
Jan. 12	Psyence Biomed approves 2026 financial strategy, board authorizes share buyback on value opportunity	RE

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company